Mark Rubinstein to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Mark Rubinstein has written about Antineoplastic Agents, Immunological.
Connection Strength
0.942
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.589
-
Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Ra Complexes Enhances Tumor Control. Cancer Immunol Res. 2019 08; 7(8):1371-1380.
Score: 0.160
-
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer. 2018 04 15; 124(8):1650-1659.
Score: 0.145
-
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
Score: 0.047